Telesis Bio, Inc. (TBIO)

Market Cap	11.37M
Revenue (ttm)	27.51M
Net Income (ttm)	-49.02M
Shares Out	30.10M
EPS (ttm)	-1.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,278
Open	0.385
Previous Close	0.410
Day's Range	0.360 - 0.417
52-Week Range	0.300 - 3.140
Beta	1.92
Analysts	Hold
Price Target	n/a
Earnings Date	May 9, 2024

About TBIO

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system, that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an i...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jun 18, 2021
• Employees: 137
• Stock Exchange: NASDAQ
• Ticker Symbol: TBIO

Financial Performance

In 2023, Telesis Bio's revenue was $27.51 million, an increase of 0.27% compared to the previous year's $27.44 million. Losses were -$49.02 million, 1.14% more than in 2022.